Pomerantz Appointed Lead Counsel in Fennec Pharmaceuticals Securities Litigation

On May 9, 2022, U.S. District Judge Catherine C. Eagles of the Middle District of North Carolina appointed Pomerantz LLP as Lead Counsel on behalf of Jeffrey D. Fisher, the Lead Plaintiff, and the class, in Fisher v. Fennec Pharmaceuticals, Inc., 22-cv-115 (M.D.N.C.). This securities action alleges that Fennec Pharmaceuticals, Inc. misled the market regarding its remediation of manufacturing issues with Pedmark, its lead product candidate, and overstated the regulatory and commercial prospects for the drug. Fennec is a biopharmaceutical company that develops product candidates for use in the treatment of pediatric cancer…